Target Name: TXNRD3
NCBI ID: G114112
Other Name(s): Thioredoxin reductase 3, transcript variant 1 | thioredoxin reductase 2 | TXNRD3NB | Thioredoxin reductase 3 | Thioredoxin-disulfide reductase 3 (TrxR3; TR3) | Thioredoxin reductase TR2 | TRXR3_HUMAN | thioredoxin and glutathione reductase | TGR | TR2 | TXNRD3IT1 | thioredoxin reductase 3 | Thioredoxin reductase 3 (isoform 1) | thioredoxin reductase 2 intronic transcript 1 | thioredoxin reductase 3 neighbor gene protein | Thioredoxin and glutathione reductase | thioredoxin reductase TR2 | thioredoxin reductase 3 intronic transcript 1 | TR2IT1 | TXNRD3 variant 1 | TXNRD3NT1 | TrxR3 | thioredoxin reductase 3 new transcript 1 | TRXR3 | TXNRD3 neighbor gene protein | thioredoxin glutathione reductase | selenoprotein TXNRD3

TXNRD3: A Potential Drug Target and Biomarker

Thioredoxin (TXR) is a protein that plays a critical role in cellular metabolism and homeostasis. It is a cytoplasmic protein that functions as a redox catalyst, involved in the transfer of electrons between reducing and oxidizing agents. There are several families of TXR, including the TXNRD3 family. In this article, we will explore the potential drug target and biomarker properties of TXNRD3.

The TXNRD3 Family

The TXNRD3 family is a subfamily of the TXR family that is characterized by the presence of a thioredoxine-219 (TXT219) gene. This gene encodes a protein that has a molecular weight of 33 kDa and a calculated pI of 5.9. The TXT219 protein is a key component of the TXNRD3 complex, which is responsible for the reduction of thioredoxin-219 to its active form, thioredoxin-219 redox.

The TXNRD3 Family in Cancer

Studies have shown that the TXNRD3 family is involved in the regulation of cellular processes that are critical for cancer development. In particular, the TXNRD3-mediated redox pathways have been implicated in the development and progression of various cancers. For example, it has been shown that the TXNRD3 gene is frequently mutated in many human cancers, including breast, ovarian, and colorectal cancers. These mutations can lead to the production of altered levels of TXNRD3 protein, which can contribute to the development of cancer.

In addition to its role in cancer development, the TXNRD3 family is also implicated in the regulation of cellular responses to chemotherapy. Many studies have shown that the TXNRD3 gene is involved in the detoxification of chemotherapy drugs, which is critical for their efficacy. The TXNRD3-mediated redox pathways can also contribute to the development of resistance to chemotherapy in cancer cells.

The TXNRD3 Family as a Drug Target

The TXNRD3 family is an attractive drug target due to its involvement in the regulation of cellular processes that are critical for cancer development and chemotherapy resistance. Several studies have shown that inhibitors of the TXNRD3 gene have been effective in treating various cancers, including breast, ovarian, and colorectal cancers. These inhibitors work by inhibiting the activity of the TXNRD3 protein, which in turn reduces the production of thioredoxin-219 and protects cancer cells from the toxic effects of chemotherapy drugs.

In addition to its potential as a drug, the TXNRD3 gene is also a potential biomarker for cancer diagnosis and prognosis. The TXNRD3 protein is often overexpressed in cancer cells, which can be used as a diagnostic marker for cancer. In addition, the TXNRD3-mediated redox pathways have been implicated in the regulation of cellular processes that are critical for cancer progression, which can be used as a biomarker for cancer prognosis.

The TXNRD3 Family as a Biomarker

The TXNRD3 family is involved in the regulation of cellular processes that are critical for cancer development and progression. As such, it is a potential biomarker for cancer diagnosis and prognosis. The TXNRD3 protein is often overexpressed in cancer cells, which can be used as a diagnostic marker for cancer. In addition, the TXNRD3-mediated redox pathways have been implicated in the regulation of cellular processes that are critical for cancer progression, which can be used as a biomarker for cancer prognosis.

In conclusion, the TXNRD3 family is a potential drug target and biomarker for cancer. The inhibition of the TXNRD3 gene has been shown to be effective in treating various cancers, including breast, ovarian, and colorectal cancers. In addition, the TXNRD3 protein is often overexpressed in cancer cells, which can be used as a diagnostic marker for cancer

Protein Name: Thioredoxin Reductase 3

Functions: Displays thioredoxin reductase, glutaredoxin and glutathione reductase activities. Catalyzes disulfide bond isomerization. Promotes disulfide bond formation between GPX4 and various sperm proteins and may play a role in sperm maturation by promoting formation of sperm structural components (By similarity)

More Common Targets

TXNRD3NB | TYK2 | TYMP | TYMS | TYMSOS | Type II Transmembrane serine protease | TYR | TYRO3 | TYRO3P | TYROBP | Tyrosine Kinase | Tyrosine-Protein Kinase ABL | Tyrosine-Protein Kinases Src | Tyrosyl-DNA phosphodiesterase TDP | TYRP1 | TYSND1 | TYW1 | TYW1B | TYW3 | U2 small nuclear ribonucleoprotein auxiliary factor | U2AF1 | U2AF1L4 | U2AF2 | U2SURP | U3 small nucleolar ribonucleoprotein (U3 snoRNP) complex | U5 small nuclear ribonucleoprotein complex | U7 snRNP complex | UACA | UAP1 | UAP1L1 | UBA1 | UBA2 | UBA3 | UBA5 | UBA52 | UBA52P1 | UBA6 | UBA6-DT | UBA7 | UBAC1 | UBAC2 | UBAC2-AS1 | UBALD1 | UBALD2 | UBAP1 | UBAP1L | UBAP2 | UBAP2L | UBASH3A | UBASH3B | UBB | UBBP1 | UBBP2 | UBBP4 | UBC | UBD | UBDP1 | UBE2A | UBE2B | UBE2C | UBE2CP3 | UBE2CP4 | UBE2D1 | UBE2D2 | UBE2D3 | UBE2D3P1 | UBE2D4 | UBE2DNL | UBE2E1 | UBE2E2 | UBE2E3 | UBE2F | UBE2F-SCLY | UBE2FP1 | UBE2G1 | UBE2G2 | UBE2H | UBE2HP1 | UBE2I | UBE2J1 | UBE2J2 | UBE2K | UBE2L1 | UBE2L3 | UBE2L6 | UBE2M | UBE2MP1 | UBE2N | UBE2NL | UBE2O | UBE2Q1 | UBE2Q2 | UBE2Q2P1 | UBE2Q2P11 | UBE2Q2P13 | UBE2Q2P16 | UBE2Q2P2 | UBE2QL1 | UBE2R2 | UBE2R2-AS1